newsfilter
← Latest News
GlobeNewswire·

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

BCRX
  • BioCryst Pharmaceuticals received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Astria Therapeutics.
  • The HSR Act clearance satisfied one condition required to consummate the Merger.
  • BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions.
  • BioCryst is a global biotechnology company commercializing ORLADEYO for hereditary angioedema & advancing a pipeline of therapeutics for rare diseases.
  • A Form S-4 registration statement containing a preliminary proxy statement/prospectus has been filed with the SEC but has not yet become effective.
  • Investors are urged to review the registration statement & proxy documents when available for important information regarding the Merger.
  • The announcement includes standard forward-looking statements & risk factors regarding potential delays, integration challenges, debt, & other uncertainties.